Takeda, Affymax announce data from multiple studies of peginesatide on anemia

Affymax, IncOct 11 2011

Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceuticals Global Research & Development Center, Inc., U.S., today announced data from multiple studies of peginesatide (formerly known as Hematide™) have been accepted for presentation at the American Society of Nephrology (ASN) Kidney Week 2011 taking place November 8-13, 2011 in Philadelphia, Pa.

Peginesatide is an investigational agent in development by Affymax and Takeda for the treatment of anemia in chronic kidney disease patients on dialysis. The companies and investigators will present seven posters, including clinical data on dosing, hemoglobin stability and safety in hemodialysis patients. Details of the poster presentations at ASN Kidney Week 2011 follow:

Friday, November 11, 2011:

• Relationship Between Peginesatide and Epoetin Doses in Hemodialysis (HD) Patients (Fishbane, et al.)
  Poster Board # FR−PO1579: 10 a.m.-12 p.m.

• Rate of Hemoglobin (Hb) Decline Following Peginesatide Dose Interruption (Besarab, et al.)
  Poster Board # FR−PO1570: 10 a.m.-12 p.m.

• Hemoglobin (Hb) Stability During Peginesatide Versus Epoetin Treatment in Hemodialysis (HD) Patients (Provenzano, et al.)
  Poster Board # FR−PO1607: 10 a.m.-12 p.m.

• Safety Results From Two Phase 3 Studies of Peginesatide Treatment for Anemia in Hemodialysis (HD) Patients (Locatelli, et al.)
  Poster Board # FR−PO1571: 10 a.m.-12 p.m.

• IV Versus SC ESA Dosing Requirements in U.S. and Non-U.S. Hemodialysis (HD) Patients (Schiller, et al.)
  Poster Board # FR−PO1601: 10 a.m.-12 p.m.

Saturday, November 12, 2011:

• Peginesatide Stimulation Allows for a Longer Lifespan of the Activated Erythropoietin Receptor (Green, et al.)
  Poster Board # SA-PO2417: 10 a.m.-12 p.m.

• In Vivo Erythropoietic Activity of Peginesatide Correlates with Erythropoietin Receptor Residence Time and Plasma Half Life (Green, et al.)
  Poster Board # SA-PO2416: 10 a.m.-12 p.m.